RGD Peptide Sequence Optimization for Integrin Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current RGD peptides, such as RGDS and RGDSP, exhibit moderate affinity to endothelial cell integrins, leading to suboptimal endothelial cell functions, and there is a need for novel peptides with higher affinity to promote angiogenesis and tissue engineering applications.

Innovation Solution

Identification and use of novel RGD peptides derived from vascular endothelium ECM proteins, such as laminin and vitronectin, which bind with higher affinity to endothelial cell integrins, and their incorporation into hydrogels to enhance endothelial cell adhesion, spreading, and proliferation, along with bioinformatics tools to screen for high-affinity peptides.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional RGD peptides (RGDS/RGDSP) are used to functionalize hydrogels, then endothelial cell adhesion and spreading are improved, but the affinity to endothelial cell integrin is only moderate, leading to suboptimal endothelial cell functions

Engineering Contradiction:
Improveendothelial cell functionVSAvoidbinding affinity
Core Design Contradiction:
ReliabilityVSStrength

Solution Approach 1:

The patent modifies the RGD peptide sequence by changing specific amino acid residues (e.g., RGDS to RGDN, RGDSP to RGDNP) to optimize the binding affinity to endothelial cell integrins while maintaining the essential cell adhesion function. This parameter change in the peptide sequence directly addresses the contradiction by improving binding strength without sacrificing reliability of endothelial cell function

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite peptide structures by combining RGD motifs with other amino acid sequences derived from ECM proteins (laminin, fibronectin, vitronectin) to generate hybrid peptides that exhibit both high integrin affinity and enhanced endothelial cell functionality. These composite peptides integrate multiple functional elements to simultaneously improve binding strength and cellular response

Inventive Principle:
Principle #40Composite materials

2Reliability

If high concentrations of angiogenic factors are used to maintain endothelial cell viability, then cell survival is improved, but the complexity of the system increases

Engineering Contradiction:
Improveendothelial cell survivalVSAvoidsystem complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the critical functional element (RGD peptide sequence) from complex ECM proteins and optimizes it independently. By focusing on the essential RGD motif and its immediate flanking residues, the invention simplifies the system while maintaining endothelial cell survival function, eliminating the need for high concentrations of complex angiogenic factors

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The optimized RGD peptides inherently provide the necessary signaling cues for endothelial cell survival and proliferation through integrin binding alone, without requiring additional exogenous growth factors. The peptides serve multiple functions (adhesion, survival, proliferation signaling) through a single molecular entity, reducing system complexity

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel RGD peptides significantly improve endothelial cell adhesion, spreading, and proliferation, promoting angiogenesis and tissue regeneration, as demonstrated by their higher binding affinity and functional validation in hydrogel microarrays and 3D alginate hydrogels.

Implementation Method 1

The RGDS (SEQ ID NO:35)/RGDSP (SEQ ID NO:34) peptides enhance the binding affinity of the constructs to αvβ3 integrin expressed on endothelial cells (EC)

Methodology Applied
Scientific EffectIntegrin-mediated binding: Adhesive

Data Source

PatentUS11150251B2Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis
Publication Date: 2021.10.19 CLEMSON UNIV RES FOUND
  • US11150251B2 patent drawing
  • US11150251B2 patent drawing
  • US11150251B2 patent drawing

AI summary

The present invention provides an in vitro method for identifying a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation for the manufacture of a diagnostic or therapeutic agent. The present invention further provides the identified compounds and pharmaceutical compositions, and assays and kits for identifying a compound or using a compound that promotes endothelial cell adhesion, endothelial cell spreading, endothelial cell migration and/or endothelial cell proliferation and is useful for bioprinting.